Healthpeak Properties (DOC) Stock Could Be A Bargain On Cash Flow Yet Fully Priced On Earnings
Healthpeak Properties has delivered a strong year to date gain, yet its valuation checks do not all point in the same direction. The Discounted Cash Flow (DCF) intrinsic value estimate flags a sizeable discount to the current price, while market based multiples suggest the stock screens as more expensive.
- The stock is up 27.5% year to date, which means anyone looking at Healthpeak Properties today is assessing it after a solid rebound.
- Future cash flow growth from its healthcare focused real estate portfolio can support the bullish case, while any pressure on property level income or funding costs may weigh on the valuation argument.
- On the broader checks Healthpeak Properties earns a mixed value score, with 3 out of 6 indicators suggesting the stock is priced more like a middle of the road opportunity than a clear bargain or a clear premium.
The issue now is whether the current share price already reflects Healthpeak Properties' intrinsic value or if that Discounted Cash Flow estimate still points to meaningful upside that the market has not priced in.
Spot opportunities that echo Healthpeak Properties' mixed valuation story by scanning our curated list of 47 high quality undervalued stocks with solid fundamentals and room for a re-rating.Does Healthpeak Properties Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model looks at what Healthpeak Properties might generate in free cash over time and brings that back to today. On this view, the business is producing a solid base of cash with latest twelve month free cash flow of about $1.29b, using adjusted funds from operations as the starting point. The projections assume cash flows that continue to grow from this level rather than swinging sharply higher or lower.
Feeding those cash flows into the two stage DCF model gives an estimated intrinsic value of about $37 per share. Compared with the current share price, the DCF output implies the stock trades at roughly a 44.6% discount to this estimate, which points to Healthpeak Properties looking undervalued on this cash flow lens.
On the DCF numbers alone, Healthpeak Properties stock screens as undervalued relative to its estimated intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Healthpeak Properties is undervalued by 44.6%. Track this in your watchlist or portfolio, or discover 47 more high quality undervalued stocks.
Has Healthpeak Properties Run Too Far on Earnings?
The P/E ratio is a useful cross check for Healthpeak Properties because earnings remain a key reference point for many real estate investors alongside cash flow metrics. On this measure, the stock trades on a P/E of about 58.7x. That is above the Health Care REITs industry average of roughly 16.8x, although it sits below the peer group average of about 67.5x.
A more tailored benchmark for Healthpeak Properties that blends factors such as its size, sector and risk profile points to a fair P/E of about 22.7x. Compared with the current P/E near 58.7x, the stock trades at a substantial premium to this implied fair level, even though it is not the richest valuation in its peer group.
On the P/E multiple, Healthpeak Properties stock currently appears more expensive than the fair ratio suggested by its fundamentals and sector backdrop.
See what the numbers say about this price — find out in our valuation breakdown.
The Healthpeak Properties Narrative: What Would Justify Today's Price?
Healthpeak Properties' valuation puzzle sets up Simply Wall St Narratives as the link between the current share price and the assumptions sitting behind it. These short scenarios spell out what would need to happen to growth, margins and earnings for the stock to end up valued materially higher or lower than today. Each one connects its number to a clear view on where growth, profitability and risk could go next that you can revisit as fresh information comes through. They are hosted on Simply Wall St's Community page, where you can see different ways other investors are thinking about those drivers.
Community views on Healthpeak Properties sit far apart, with one side leaning into growth optionality and the other focused on execution and tenant risk.
Bull case: 24% undervalued
"Healthpeak's unique, high-concentration positions in premier high-growth Sunbelt and innovation markets, deep health system relationships, and a war chest for opportunistic acquisitions, mean future accretive investments could drive a step-change in AFFO per share growth as capital market conditions shift..."
Read the full Bull Case to see why Healthpeak Properties could be undervalued
Bear case: 13% overvalued
"Although Healthpeak Properties benefits from sustained demand drivers such as the aging U.S. population and the ongoing shift toward outpatient care, the company faces potential revenue headwinds from execution risk and occupancy volatility within its life science segment, as smaller biotech tenants continue to struggle accessing capital..."
Read the full Bear Case to see why Healthpeak Properties could be overvalued
Do you think there's more to the story for Healthpeak Properties? Head over to our Community to see what others are saying!
The Bottom Line
Healthpeak Properties presents a split valuation story. The Discounted Cash Flow (DCF) intrinsic value estimate points to a sizeable discount, while the P/E based view signals the stock screens as overvalued relative to its tailored fair ratio. That gap largely comes down to how much weight you place on long term cash generation versus current market expectations for growth and risk. The key question from here is whether Healthpeak Properties can convert its healthcare real estate portfolio into the steady cash flow path implied by the DCF, or whether execution and tenant risks justify the richer multiple investors are currently paying.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com